Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Ibrutinib in Ibrutinib-Relapsed Mantle Cell Lymphoma
NCT03617484Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in mantle cell lymphoma (MCL), sponsored by University of Michigan Rogel Cancer Center. Planned start Jul 2020; status: withdrawn.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03617484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617484.